Serum PIVKA – II Level at Test Zone Diagnostic Center

Introduction to Serum PIVKA – II Level Testing

The Serum PIVKA – II Level test is a highly specialized laboratory investigation used primarily as a biomarker for the detection, monitoring, and prognostic evaluation of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. PIVKA-II stands for Protein Induced by Vitamin K Absence or Antagonist-II. It is also clinically referred to as Des-gamma-carboxyprothrombin (DCP). Under normal physiological conditions, hepatocytes synthesize prothrombin, a critical blood-clotting factor, through a process that requires vitamin K. Vitamin K acts as a cofactor for the enzyme gamma-glutamyl carboxylase, which carboxylates specific glutamic acid residues on the prothrombin precursor, converting it into active prothrombin. However, in the absence of vitamin K, in the presence of vitamin K antagonists like warfarin, or within malignant hepatocytes, this carboxylation process is severely impaired. Consequently, an abnormal, non-functional form of prothrombin—PIVKA-II—is released into the systemic circulation.

At Test Zone Diagnostic Center, the Serum PIVKA – II Level test is performed using state-of-the-art chemiluminescent enzyme immunoassay (CLEIA) technology. This advanced methodology offers exceptional sensitivity and specificity, allowing for the detection of minute concentrations of PIVKA-II in the blood. Evaluating PIVKA-II levels is of paramount clinical importance because malignant liver cells often exhibit a localized acquired vitamin K deficiency and dysfunctional carboxylation mechanisms, leading to elevated PIVKA-II production even when systemic vitamin K levels are normal. This makes PIVKA-II an invaluable diagnostic tool, particularly when used in conjunction with Alpha-Fetoprotein (AFP), as the two biomarkers are complementary and significantly increase the diagnostic yield for early-stage liver malignancies. Understanding these levels helps oncologists, hepatologists, and gastroenterologists make informed decisions regarding patient care, treatment efficacy, and long-term surveillance.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your Serum PIVKA – II Level test at Test Zone Diagnostic Center, patients are advised to adhere to the following preparation guidelines:

• Fasting Requirements: While a strict fast is not always mandatory, a fasting period of 8 to 12 hours prior to sample collection is highly recommended to prevent lipemia (excess fat in the blood), which can interfere with the optical readings of the immunoassay.
• Medication Disclosure: It is critical to inform your healthcare provider and the laboratory staff of all medications you are currently taking. Specifically, vitamin K antagonists such as Warfarin (Coumadin), phenprocoumon, or acenocoumarol will artificially elevate PIVKA-II levels, rendering the test inaccurate for cancer screening.
• Dietary Supplements: Avoid taking high-dose vitamin K supplements or multivitamins containing vitamin K for at least 48 to 72 hours before the test, unless specifically instructed otherwise by your physician, as this can artificially lower PIVKA-II levels.
• Antibiotic Therapy: Inform the laboratory if you have recently completed a course of broad-spectrum antibiotics, as these can alter gut microbiota, reduce endogenous vitamin K synthesis, and potentially affect test outcomes.
• Hydration: Stay well-hydrated by drinking plenty of plain water before the procedure, as this facilitates easier venous access and smooth sample collection.

During the Procedure

The Serum PIVKA – II Level test is a standard venipuncture procedure conducted by experienced phlebotomists at Test Zone Diagnostic Center. The process is designed to be quick, safe, and minimally invasive:

• Patient Positioning: You will be asked to sit comfortably in a specialized blood collection chair or lie down if you have a history of dizziness or fainting during blood draws.
• Sanitization and Preparation: The phlebotomist will locate a suitable vein, typically in the antecubital fossa (the crook of the elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) and allowed to air dry to prevent contamination.
• Sample Collection: A sterile, single-use needle attached to a vacuum collection tube (typically a serum separator tube or red-top tube) is gently inserted into the vein. You may feel a brief, mild pinch or prick. The required volume of blood (usually 3 to 5 milliliters) is drawn into the tube.
• Post-Collection Care: Once the sample is collected, the needle is carefully withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad or cotton ball to promote hemostasis. An adhesive bandage is then applied.
• Duration and Safety: The entire procedure takes less than 5 to 10 minutes. All materials used are sterile and disposable, eliminating any risk of cross-contamination. Patients can resume their normal daily activities immediately after the blood draw.

When is a Serum PIVKA – II Level Performed?

Screening and Surveillance of Hepatocellular Carcinoma (HCC)

Physicians frequently request the Serum PIVKA – II Level test for patients who are at high risk of developing hepatocellular carcinoma. This includes individuals diagnosed with chronic hepatitis B or C infections, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), or liver cirrhosis of any etiology. Because HCC often develops silently without early symptoms, regular surveillance using PIVKA-II, combined with abdominal ultrasonography, assists in detecting malignant changes at an early, resectable stage, significantly improving patient survival rates.

Monitoring Response to Hepatocellular Carcinoma Therapy

In patients who have already been diagnosed with HCC and have undergone therapeutic interventions—such as surgical resection, liver transplantation, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), or systemic chemotherapy—the Serum PIVKA – II Level test is performed to monitor treatment response. A significant post-treatment decline in PIVKA-II levels indicates a favorable response and successful tumor reduction, whereas persistently high or rising levels suggest incomplete tumor ablation or active disease.

Surveillance for Tumor Recurrence

Following successful treatment of liver cancer, patients require lifelong monitoring to detect potential disease recurrence. The Serum PIVKA – II Level test is an essential component of this post-therapeutic surveillance protocol. Regular testing allows oncologists to detect recurrent tumors long before they become visible on standard imaging modalities, enabling prompt initiation of secondary treatments.

Evaluating Unexplained Vitamin K Deficiency and Malabsorption

Beyond its oncological applications, the Serum PIVKA – II Level test is requested when a clinician suspects subclinical vitamin K deficiency or severe intestinal malabsorption. Conditions such as celiac disease, Crohn’s disease, chronic pancreatitis, or primary biliary cholangitis can impair the absorption of fat-soluble vitamins, including vitamin K. Measuring PIVKA-II provides a highly sensitive functional marker of vitamin K status at the cellular level, far exceeding the sensitivity of standard prothrombin time (PT) tests.

Differentiating Benign Liver Nodules from Malignant Lesions

When routine imaging studies, such as ultrasound or CT scans, reveal suspicious nodules or masses in the liver, the Serum PIVKA – II Level test is performed to help differentiate benign lesions (like hepatic hemangiomas, focal nodular hyperplasia, or adenomas) from malignant hepatocellular carcinoma. Elevated PIVKA-II levels strongly point toward malignancy, assisting multidisciplinary medical teams in formulating precise diagnostic and biopsy strategies.

What Does a Serum PIVKA – II Level Detect?

The Serum PIVKA – II Level test is highly sensitive to metabolic and pathological changes within hepatocytes. It detects several critical clinical conditions and physiological states, including:

• Early-stage hepatocellular carcinoma (HCC) in high-risk cirrhotic patients.
• Advanced or metastatic hepatocellular carcinoma.
• Microvascular invasion of liver cancer cells into the portal vein.
• Subclinical vitamin K deficiency before clinical bleeding symptoms manifest.
• Inadequate dietary intake of vitamin K.
• Malabsorption of fat-soluble vitamins due to inflammatory bowel disease (IBD).
• Biliary obstruction leading to impaired fat and vitamin K absorption.
• The pharmacological effect of vitamin K antagonists (such as Warfarin).
• The presence of dysfunctional gamma-glutamyl carboxylase enzymes in hepatocytes.
• Tumor recurrence in post-hepatectomy or post-ablation patients.
• Efficacy of transarterial chemoembolization (TACE) in treating liver tumors.
• Active tumor progression or therapeutic failure in patients undergoing systemic immunotherapy.
• Chronic liver parenchymal damage associated with long-standing Hepatitis B infection.
• Severe liver injury associated with chronic Hepatitis C infection.
• Alcohol-induced hepatic injury and progressive alcoholic steatohepatitis.
• Advanced non-alcoholic steatohepatitis (NASH) with high risk of malignant transformation.
• The functional impact of broad-spectrum antibiotic therapy on intestinal vitamin K synthesis.
• Congenital or acquired disorders of vitamin K metabolism.
• Primary biliary cholangitis (PBC) and its systemic metabolic complications.
• Primary sclerosing cholangitis (PSC) affecting hepatic and biliary function.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely results are crucial for effective clinical decision-making and patient peace of mind. The Serum PIVKA – II Level test is processed using fully automated, high-throughput immunoassay platforms that undergo rigorous daily quality control checks. The standard turnaround time for this specialized test is typically within 24 to 48 hours from the time of sample collection.

Once the analysis is complete, the laboratory report is thoroughly reviewed and signed off by a consultant pathologist. Patients and their referring physicians are immediately notified via SMS when the report is ready. Reports can be accessed and downloaded securely through the Test Zone Diagnostic Center online portal or mobile application, ensuring seamless integration with your digital health records. Physical copies of the report are also available for collection at our main reception desk.

Serum PIVKA – II Level Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum PIVKA-II Concentration	Less than 40 mAU/mL (may vary slightly by assay)	Elevated levels (>40 mAU/mL), often exceeding hundreds or thousands of mAU/mL in malignancies.
Vitamin K Status	Sufficient systemic and intrahepatic vitamin K levels	Functional vitamin K deficiency due to dietary lack, malabsorption, or drug antagonism.
Hepatocellular Carcinoma Risk	Low probability of active HCC (when correlated with imaging)	High probability of primary hepatocellular carcinoma or active tumor recurrence.
Portal Vein Invasion Risk	Low risk of microvascular tumor invasion	Markedly elevated levels (>400 mAU/mL) strongly correlate with portal vein tumor thrombosis.
Anticoagulant Therapy Impact	No interference (patient not on vitamin K antagonists)	Artificially elevated PIVKA-II levels due to therapeutic Warfarin or Coumadin administration.
Intestinal Absorption Capacity	Normal absorption of fat-soluble vitamins	Elevated PIVKA-II secondary to fat malabsorption (e.g., Celiac disease, chronic pancreatitis).
Post-Treatment Tumor Status	Undetectable or baseline levels post-resection	Persistent elevation or rising trend indicating residual tumor or early recurrence.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Serum PIVKA – II Level?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, biochemists, and technologists specializing in advanced tumor marker assays.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict international laboratory standards and participates in rigorous external quality assurance programs.
• Professional Reporting: Our reports are comprehensive, easy to read, and include detailed reference ranges to assist your physician in clinical decision-making.
• Modern Diagnostic Approach: We utilize state-of-the-art automated chemiluminescent immunoassay technology for superior precision and accuracy.
• Comfortable Environment: Our collection centers are designed to provide a clean, hygienic, and stress-free experience for all patients.
• Convenient Location: Easily accessible facilities with ample parking and comfortable waiting areas.
• Commitment to Accurate Diagnosis: We ensure meticulous sample handling, from collection to analysis, to deliver highly reliable results you can trust.